Chapter 3: Results
2. The patient sera with anti-HpHSP60 antibodies could enhance the expressions
The anti-HpHSP60 antibodies in sera of H. pylori-infected patients were measured by ELISA (Fig 3). According to the results, samples were divided into two groups: low titer group and high titer group (A: relative titer ratio < 2.2; B:
relative titer ratio > 2.2). The mean value ± SD of serum antibodies to H.
pylori-positive patients determined by an ELISA in group A (n = 8) and B (n = 8)
were 1.59 ± 0.36 and 2.82 ± 0.39.
To determine whether the anti-HpHSP60 antibodies in sera of H.
pylori-infected patients could lower the ability of HpHSP60 to stimulate
proinflammatory cytokine secretions, the patients’ sera from A and B groups were respectively incubated with rHpHSP60. The inductive amounts of TNF-α or IL-8 were determined and the results showed no matter which sera all could increase the expressions of TNF-α (Fig. 4A; A group: 770.57 ± 147.30 and B group: 740.75 ± 105.75 pg/ml) or IL-8 (Fig. 4B; A group : 10943.35 ± 4935.40 and B group: 10280.29 ± 2148.42 pg/ml) than the samples without sera
treatments (TNF-α: 554.99 ± 35.33 and IL-8:4355.42 ± 331.12 pg/ml). There were no significant differences between low titer group (A group) and high titer group (B group). In addition, the patients’ sera alone without rHpHSP60 treatments could not result in any increases in the expressions of TNF-α or IL-8.
3. The effects of mouse and rabbit anti-HpHSP60 polyclonal antibodies on the abilities of HpHSP60 to induce expressions of TNF-α and IL-8.
To test the hypothesis that the anti-HpHSP60 polyclonal antibodies in H.
pylori-infected patients’ sera could enhance the abilities of HpHSP60 to
stimulate the expressions of TNF-α or IL-8 secretion, anti-HpHSP60 polyclonal antibodies derived from mice or rabbit immunized with rHpHSP60 were used to study the effects of polyclonal antibodies on the activities of HpHSP60 for inductions of proinflammatory cytokines. Combining with HpHSP60, all mouse anti-HpHSP60 sera significantly increased the expressions of TNF-α (1674.49 ± 188.12 pg/ml) or IL-8 (22402.75 ± 3341.75 pg/ml) comparing to the samples without sera treatment (TNF-α: 599.25 ± 19.93 and IL-8: 4587.82 ± 965.07 pg/ml) (Fig 5). While rHpHSP60 were treated with normal sera derived from naïve mice, TNF-α and IL-8 expressions were no significantly increase.
Similarly, the sera only without rHpHSP60 treatments could not cause any
significant TNF-α and IL-8 expressions.
All treatments with different doses of rabbit anti-HpHSP60 polyclonal antibodies facilitated rHpHSP60 to induce the expressions of TNF-α and IL-8, which were in accordance with the mouse sera (Fig. 6 A and B).
4. The effects of monoclonal antibodies on the abilities of HpHSP60 to induce expressions of TNF-α and IL-8.
So far, the previous results have revealed that sera against HpHSP60 no matter it were from patients, mice or rabbit can enhance the abilities of rHpHsp60 to stimulate TNF-α or IL-8 secretions. However, certain facts but not anti-HpHSP60 antibodies in serum may involve in or dominate this enhancive effect, which still could not be excluded. Thus, monoclonal antibodies against HpHSP60 were produced to verify the phenomenon. As shown in Table 1, from 390 hybridomas in a primary screening, 260 hybridomas could react with rHpHSP60 and 4 hybridomas were able to recognize the wild type HpHSP60.
Finally, 3 hybridomas were established and used in this study (designated as 5A8, 5A12 and 5B11) (Table 1).
Different dosages (0.4, 2, 10, 50 µg/ml) of three monoclonal antibodies were incubated with rHpHSP60 to treat THP-1 cells. All mAbs (5A8, 5A12 and
5B11) significantly increased the abilities of HpHSP60 to trigger the expressions of TNF-α comparing to the samples without mAb treatment (Fig 7A). In IL-8, almost doses of tree mAbs could significantly enhance the secretions, except of 0.4 µg/ml of 5A8, 50 µg/ml of 5A12 and 50 µg/ml of 5B11 (Fig 7B). In addition, these mAbs could not enhance the secretions of proinflmmatory cytokines by themselves.
The previous results indicated that the additional mAbs could cause the enhancive effect but the antigen-binding activities were essential for the enhancive effect or not still was unclear. Thus, the non-related Abs (anti-bovine haptoglobin) were prior interacted with rHpHSP60 and the results showed that TNF-α or IL-8 expressions were higher decreased as additions of non-related Abs were more (Fig. 8A and B). Further, whether the non-related mAb could affect the enhancive effect of specific anti-HpHSP60 mAbs on the cytokines expressions induced by HpHSP60 was examined. Figure 9A-C showed the abilities of 5A8, 5A12 and 5B11 to enhance expressions of TNF-α was significantly suppressed by non-related mAbs. Similarly, the non-related mAbs also decreased the specific anti-HpHSP60 mAbs’ enhancive effects on the IL-8 expressions (Fig. 10A-C).
Chapter 4: Discussion
In this study, we explored that the anti-HpHSP60 antibodies in patients’ sera could significantly enhance the ability of HpHSP60 to induce TNF-α or IL-8.
According the previous literatures, anti-HpHSP60 antibodies could be detected in H. pylori infected patients’ sera (Yunoki, Yokota et al. 2000; Ishii, Yokota et al.
2001; Tanaka, Kamada et al. 2009) and our results agreed well with these clinical examinations. Figure 3 pointed out that all H. pylori-infected patients had antibodies against HpHSP60 in their sera.
Furthermore, Dr. Perez-Perez et al. demonstrated that the titer of anti-HpHSP60 was correlated with the degree of gastric mucosal inflammation (Hussain, Shiratsuchi et al. 2000). As the knowledge from the literatures, extracellular HSPs are the most powerful ways of sending a ‘danger signal’ to the immune system in order to generate the responses that can help the organism manage an infection or disease and they are associating with the innate or adaptive immune systems activation (Ellis 1990; Young 1990). Furthermore, microbial HSP60s have been explored as an immunodominant antigen since it could induce powerful immune response after infection (Habich, Kempe et al.
2003). Bacterial HSPs such as HSP65 of Mycobacterial leprae have also been reported that they have the capability to induce releases of TNF-α, IL-6, and
IL-8 from human monocytic cells (Friedland, Shattock et al. 1993). Similarly, HpHSP60 has been reported to induce proinflammatory cytokines including IL-6, and IL-8 from human monocytic cells and/or gastric epithelium cells (Lin, Ayada et al. 2005; Zhao, Yokota et al. 2007), which is dominated by TLR-2 and TLR-4 pathways (Gobert, Bambou et al. 2004; Takenaka, Yokota et al. 2004).
Furthermore, some reports indicate that HSP60 is located on the surface of the bacteria (Yamaguchi, Osaki et al. 1996). These data indicate that hsp60 develops a tendency to be recognized by the host and may be closely related to H. pylori-induced inflammation. However, the role of anti-HpHSP60 antibodies in this inflammation is not clear. Ishii et al. have reported that the levels of IgG1 antibodies to HSP60 are elevated and it is closely associated with MALT lymphoma in H. pylori infected patients (Ishii, Yokota et al. 2001). Moreover, Hussain et al. also indicated the specific anti-PPD antibodies (IgG1) could up-regulate the activity of PPD to induce proinflammatory cytokines (Hussain, Shiratsuchi et al. 2000), which is similar as our finding on HpHSP60. In addition, different polyclonal anti-sera derived from different species confirm this effect again (Fig. 5 and 6), which indicated that the difference in species did not involved in the mechanism of enhancive effect on induction of proinflammatory cytokine release.
To sure the effect is because the anti-HpHSP60 antibodies but not the other factors in sera, we produced monoclonal antibodies against HpHSP60 to exclude the effects of non-specific anti-HpHSP60 antibodies or other factors in sera. Our data showed all purified mAbs (5A8, 5A12 and 5B11) could also cause higher levels of TNF-α or IL-8 expression in monocytes (Fig 7). Similar enhancive effect on pathogenesis by monoclonal antibodies is also explored for to H.
capsulatum HSP60 (Guimaraes, Frases et al. 2009). So far, our results indicated
the anti-HpHSP60 antibodies could result in this enhancive effect. Although these results revealed that different affinity of mAbs would cause different influences on cytokines expressions, seemingly the affinity is not the mechanism for the enhancive effect.
Our results indicated the specific anti-HpHSP60 antibodies could raise the capability of HpHSP60 to enhance the expressions of proinlammatory cytokines but the mechanisms were still unclear. Previous literatures have explored that HpHSP60 could induce expressions of proinflammatory cytokines through TLR-2 and TLR-4 pathways (Gobert, Bambou et al. 2004; Takenaka, Yokota et al. 2004). Although which factor(s) involved in the enhancive effects of specific antibodies did not completely identify, our results have indicated the non-related mAb could decrease the enhancive effect of specific mAbs (Fig 9 and 10).
Therefore, we proposed that Fc receptors may involve in the enhancive effects of specific antibodies. It has been reported that the Fc receptor can interact with the antibody’ Fc region (Raghavan and Bjorkman 1996) and the recent study has further found that Fcγ receptors can trigger inflammatory reactions in response to immunoglobulin-opsonized pathogens or antigen-antibody complexes (Liu, Masuda et al. 2005). Thus, prior combination of the anti-HpHSP60 antibody with HpHSP60 should posterior bind to Fc receptor, which could increase the probability of HpHSP60 to interact with TLR. Besides, the engagement of the Fc receptor could also trigger the signaling to contribute to the enhancive effect.
Finally, we indicated that the antibodies against HpHSP60 could enhance the ability of HpHSP60 to induce proinflammatory cytokines secretion in monocytes. In addition, we proposed that Fc receptor on monocyte involved in the enhancive effect of the anti-HpHSP60 antibodies. H. pylori infection causes the gastric diseases by induction of chronic inflammation. Although several virulent factors in this pathogenic microorganism have been identified, the pathogenic immunity induced by these factors are rare discussed. According our results, we proposed that patients’ the anti-HpHSP60 antibodies may bind to HpHSP60 to result in more serious inflammation and lead to more serious tissue damages in infectious sites.
Figures and Legends
Figure 1. SDS-PAGE and Western blot analyses of recombinant HpHSP60.
Left panel: Coomassie blue staining of rHpHSP60 run on a 10% SDS-PAGE under non-reducing and reducing conditions. Right panel: Western blot analysis of rHpHSP60 run on a 10% SDS-PAGE under non-reducing and reducing conditions. Lane M means the molecular marker and sample reacted without or with β-ME buffer was non-reducing conditions (lanes 1) and reducing conditions (lanes 2).
1 2
Figure 2. Production of proinflammatory cytokines in THP-1 cells. (A)
IL-1β, (B) IL-6, (C) IL-8 and (D) TNF-α secretion in THP-1 cells were measured in response to rHpHsp60. The THP-1 cells (5× 105) were treated and incubated with the rHpHsp60s (final concentration of 10 µg/ml) in 24-well plate for 24 h, and the cytokines in the medium were determined by ELISA. Results are representative three independent experiments. , ★ P＜0.001 compared to samples without rHpHsp60 treatment. (n = 3). Source from (Lin 2008)
(A) (B)
(C) (D)
Figure 3. The relative ratio of serum antibodies to HpHSP60 in H.
pylori-positive patients. The titer of anti-HpHSP60 antibodies from sera of H.
pylori-positive patients were analyzed using ELISA. And there are four
symptoms of samples including gastric cancer, gastritis, duodenal ulcer, and gastric ulcer. According to the titer, samples were divided into two groups including low titer group (A group, n = 8) and high titer group (B group, n = 8).
Results are shown as mean ± SD.
A B
(A.)
(B.)
-* **
HpHSP60 + + + Patients’ serum A B
-***
*
HpHSP60 + + Patients’ serum A B
+
Figure 4. The patients sera with anti-HpHSP60 antibodies could enhance the expressions of TNF-α and IL-8. The expressions of TNF-α (A.) and IL-8
(B.) were assessed by ELISA as described in material and method section. The patients’ sera of A and B groups were 1:250 diluted and incubated with HpHSP60 (5µg/ml) for 30 min then treated THP-1 cells (5×105 /well) for 24 hour. The horizontal lines of the data were expressed as the sample only with cells. Results are shown as mean ± SD. *p < 0.05, **p < 0.01 and ***p < 0.001 as compare to samples without sera treatments.
(A.)
(B.)
HpHSP60 + + Polyclonal Abs - +
***
HpHSP60 + + Polyclonal Abs - +
***
Figure 5. The effect of mouse polyclonal antibodies on the abilities of HpHSP60 to induce expressions of TNF- α and IL-8. The expressions of
TNF-α (A.) and IL-8 (B.) were assessed by ELISA as described in material and method section. The mouse anti-HpHSP60 polyclonal antibodies were diluted (1:1000) and incubated with HpHSP60 (5µg/ml) for 30 min then treated THP-1 cells (5×105 /well) for 24 hour. The horizontal lines of the data were expressed as the sample only with cells. Results are shown as mean ± SD. ***p< 0.001 as compare to samples without sera treatments.
(A.)
Figure 6. The effect of rabbit polyclonal antibodies on the abilities of HpHSP60 to induce expressions of TNF- α and IL-8. The expressions of
TNF-α (A.) and IL-8 (B.) were assessed by ELISA as described in material and method section. The rabbit anti-HpHSP60 polyclonal antibodies were diluted (1:1000, 1:200, 1:100 and 1:50) and incubated with HpHSP60 (5µg/ml) for 30 min then treated THP-1 cells (5×105 /well) for 24 hour. Results are shown as mean ± SD. **p< 0.01 and ***p< 0.001 as compare to samples only with HpHSP60 treatments. (n = 3) R polyclonal Abs: Rabbit anti-HpHSP60 polyclonal antibodies.
Table1. The characterizations of monoclonal Abs
(A.)
mAbs TNF-alpha conc. (pg/ml) 5A8
5A12
mAbs IL-8 conc. (pg/ml) 5A8
5A12
Figure 7. The effect of monoclonal antibodies on the abilities of HpHSP60 to induce expressions of TNF- α and IL-8. The expressions of TNF-α (A.) and
IL-8 (B.) were assessed by ELISA as described in material and method section.
At first, HpHSP60 (5µg/ml) were incubated with various concentration of monoclonal antibodies (5A8, 5A12 and 5B11) including 0.4, 2, 10, 50 µg/ml for 30 min then treated THP-1 cells (5×105 /well) for 24 hour. Then the supernatants were harvested to be examined for the cytokines expression level. Results are shown as mean ± SD. *p< 0.05, **p< 0.01, ***p< 0.001 as compare to samples only with HpHSP60 treatments. (n = 3)
(A.)
TNF-alpha conc. (pg/ml) non-related mAb
HpHSP60 0 5 5 5 5 5
Figure 8. The effect of non-related mAb on the abilities of HpHSP60
to induce expressions of TNF- α and IL-8. HpHSP60 (5µg/ml) were incubated
with various concentration of non-related mAb including 0.4, 2, 10, 50 µg/ml for 30 min then treated THP-1 cells (5×105 /well) for 24 hour. And the TNF-α (A.) and IL-8 (B.) levels in supernatant were measured by ELISA.
Results are shown as mean ± SD. *p< 0.05, **p< 0.01, ***p< 0.001 as compare to samples only with HpHSP60 treatments. (n = 3) Non-related mAb: The monoclonal antibody against haptoglobin.
(A.)
Figure 9. The non-related mAbs interfere with anti-HpHSP60 monoclonal
antibodies to enhance the abilities of HpHSP60 to induce expressions of TNF- α. (A.) 5A8, (B.) 5A12 and (C.) 5B11 (10 µg/ml) were incubated with
HpHSP60 (5µg/ml) for 30 min then treated to THP-1 cells (5×105 /well) which were pretreated with the non-related Ab (50µg/ml) for 1 hr then incubated for 24 hr. And the TNF-α levels in supernatant were measured by ELISA. Results are shown as mean ± SD. *p< 0.05, **p< 0.01, as compare to samples only with HpHSP60 treatments or samples with non-related Ab treatments. (n = 3) Non-related mAb: The monoclonal antibody against haptoglobin.
(A.)
Figure 10. The non-related mAbs interfere with anti-HpHSP60 monoclonal
antibodies to enhance the abilities of HpHSP60 to induce expressions of IL-8. (A.) 5A8, (B.) 5A12 and (C.) 5B11 (10 µg/ml) were incubated with
HpHSP60 (5µg/ml) for 30 min then treated to THP-1 cells (5×105 /well) which were pretreated with the non-related Ab (50µg/ml) for 1 hr then incubated for 24 hr. And the IL-8 levels in supernatant were measured by ELISA. Results are shown as mean ± SD. **p< 0.01 and ***p< 0.001, as compare to samples only with HpHSP60 treatments or samples with non-related Ab treatments. (n = 3) Non-related Ab: anti-bovin haptoglobin antibody.
References
(1994). "Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994." IARC Monogr Eval Carcinog Risks Hum 61: 1-241.
Austin, J. W., P. Doig, et al. (1992). "Structural comparison of urease and a GroEL analog from Helicobacter pylori." J Bacteriol 174(22): 7470-3.
Barrios, C., C. Tougne, et al. (1994). "Specificity of antibodies induced after immunization of mice with the mycobacterial heat shock protein of 65 kD." Clin Exp Immunol 98(2): 224-8.
Bayerdorffer, E., A. Neubauer, et al. (1995). "Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group." Lancet 345(8965): 1591-4.
Blaser, M. J. (1990). "Helicobacter pylori and the pathogenesis of gastroduodenal inflammation." J Infect Dis 161(4): 626-33.
Bruce, M. G. and H. I. Maaroos (2008). "Epidemiology of Helicobacter pylori infection." Helicobacter 13 Suppl 1: 1-6.
Bulut, Y., E. Faure, et al. (2002). "Chlamydial heat shock protein 60 activates macrophages and endothelial cells through Toll-like receptor 4 and MD2 in a MyD88-dependent pathway." J Immunol 168(3): 1435-40.
Bulut, Y., K. Shimada, et al. (2009). "Chlamydial heat shock protein 60 induces acute pulmonary inflammation in mice via the Toll-like receptor 4- and
MyD88-dependent pathway." Infect Immun 77(7): 2683-90.
Correa, P. (1992). "Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention." Cancer Res 52(24): 6735-40.
Cutler, A. F. and V. M. Prasad (1996). "Long-term follow-up of Helicobacter pylori serology after successful eradication." Am J Gastroenterol 91(1): 85-8.
Dunn, B. E., N. B. Vakil, et al. (1997). "Localization of Helicobacter pylori urease and heat shock protein in human gastric biopsies." Infect Immun 65(4):
1181-8.
Eidt, S., M. Stolte, et al. (1994). "Helicobacter pylori gastritis and primary gastric non-Hodgkin's lymphomas." J Clin Pathol 47(5): 436-9.
Ellis, R. J. (1990). "The molecular chaperone concept." Semin Cell Biol 1(1):
1-9.
Eslick, G. D., L. L. Lim, et al. (1999). "Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis." Am J Gastroenterol 94(9):
2373-9.
Friedland, J. S., R. Shattock, et al. (1993). "Mycobacterial 65-kD heat shock protein induces release of proinflammatory cytokines from human monocytic cells." Clin Exp Immunol 91(1): 58-62.
Gobert, A. P., J. C. Bambou, et al. (2004). "Helicobacter pylori heat shock protein 60 mediates interleukin-6 production by macrophages via a toll-like receptor (TLR)-2-, TLR-4-, and myeloid differentiation factor 88-independent mechanism." J Biol Chem 279(1): 245-50.
Goodwin, C. S. and J. A. Armstrong (1990). "Microbiological aspects of Helicobacter pylori (Campylobacter pylori)." Eur J Clin Microbiol Infect Dis 9(1): 1-13.
Goodwin, C. S., R. K. McCulloch, et al. (1985). "Unusual cellular fatty acids and distinctive ultrastructure in a new spiral bacterium (Campylobacter pyloridis) from the human gastric mucosa." J Med Microbiol 19(2): 257-67.
Guimaraes, A. J., S. Frases, et al. (2009). "Monoclonal antibodies to heat shock protein 60 alter the pathogenesis of Histoplasma capsulatum." Infect Immun 77(4): 1357-67.
Habich, C., K. Kempe, et al. (2003). "Different heat shock protein 60 species share pro-inflammatory activity but not binding sites on macrophages." FEBS
Lett 533(1-3): 105-9.
Huang, J. Q. and R. H. Hunt (2003). "The evolving epidemiology of
Helicobacter pylori infection and gastric cancer." Can J Gastroenterol 17 Suppl B: 18B-20B.
Hussain, R., H. Shiratsuchi, et al. (2000). "PPD-specific IgG1 antibody subclass upregulate tumour necrosis factor expression in PPD-stimulated monocytes:
possible link with disease pathogenesis in tuberculosis." Clin Exp Immunol 119(3): 449-55.
Ishii, E., K. Yokota, et al. (2001). "Immunoglobulin G1 antibody response to Helicobacter pylori heat shock protein 60 is closely associated with low-grade gastric mucosa-associated lymphoid tissue lymphoma." Clin Diagn Lab
Immunol 8(6): 1056-9.
Jolly, C. and R. I. Morimoto (2000). "Role of the heat shock response and
molecular chaperones in oncogenesis and cell death." J Natl Cancer Inst 92(19):
1564-72.
Kosunen, T. U., K. Seppala, et al. (1992). "Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori." Lancet 339(8798): 893-5.
Lin, S. N., K. Ayada, et al. (2005). "Helicobacter pylori heat-shock protein 60 induces production of the pro-inflammatory cytokine IL8 in monocytic cells." J Med Microbiol 54(Pt 3): 225-33.
Lin, Y., Y (2008). "Heat shock protein 60 of helicobacter pylori induces proinflammatory cytokined secretion but diminishes monocyte activation."
Lindquist, S. (1986). "The heat-shock response." Annu Rev Biochem 55:
1151-91.
Liu, Y., E. Masuda, et al. (2005). "Cytokine-mediated regulation of activating and inhibitory Fc gamma receptors in human monocytes." J Leukoc Biol 77(5):
767-76.
Malaty, H. M., N. D. Logan, et al. (2001). "Helicobacter pylori infection in
preschool and school-aged minority children: effect of socioeconomic indicators and breast-feeding practices." Clin Infect Dis 32(10): 1387-92.
Mao, S. J., A. E. Rechtin, et al. (1988). "Monoclonal antibodies that distinguish between active and inactive forms of human postheparin plasma hepatic
triglyceride lipase." J Lipid Res 29(8): 1023-9.
Mao, S. J., A. E. Rechtin, et al. (1990). "Characterization of a monoclonal antibody specific to the amino terminus of the alpha-chain of human fibrin."
Thromb Haemost 63(3): 445-8.
Mattsson, A., M. Quiding-Jarbrink, et al. (1998). "Antibody-secreting cells in the stomachs of symptomatic and asymptomatic Helicobacter pylori-infected subjects." Infect Immun 66(6): 2705-12.
Morimoto, R. I. (1993). "Cells in stress: transcriptional activation of heat shock genes." Science 259(5100): 1409-10.
Parsonnet, J., S. Hansen, et al. (1994). "Helicobacter pylori infection and gastric lymphoma." N Engl J Med 330(18): 1267-71.
Perez-Perez, G. I., W. R. Brown, et al. (1994). "Correlation between serological and mucosal inflammatory responses to Helicobacter pylori." Clin Diagn Lab Immunol 1(3): 325-9.
Perez-Perez, G. I., A. F. Cutler, et al. (1997). "Value of serology as a noninvasive method for evaluating the efficacy of treatment of Helicobacter pylori
infection." Clin Infect Dis 25(5): 1038-43.
Raghavan, M. and P. J. Bjorkman (1996). "Fc receptors and their interactions with immunoglobulins." Annu Rev Cell Dev Biol 12: 181-220.
Ritossa, F. (1962). "A new puffing pattern induced by temperature shock and DNP in Drosophila." Experientia 18: 571-573.
Sarfati, M., S. Fournier, et al. (1992). "Expression, regulation and function of human Fc epsilon RII (CD23) antigen." Immunol Res 11(3-4): 260-72.
Selvaraj, P., N. Fifadara, et al. (2004). "Functional regulation of human neutrophil Fc gamma receptors." Immunol Res 29(1-3): 219-30.
Sommer, F., G. Faller, et al. (1998). "Antrum- and corpus mucosa-infiltrating CD4(+) lymphocytes in Helicobacter pylori gastritis display a Th1 phenotype."
Infect Immun 66(11): 5543-6.
Sulica, A., W. H. Chambers, et al. (1995). "Divergent signal transduction
pathways and effects on natural killer cell functions induced by interaction of Fc
pathways and effects on natural killer cell functions induced by interaction of Fc